A practical review on carfilzomib in multiple myeloma

Carfilzomib, a second‐generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma a...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2016-06, Vol.96 (6), p.564-577
Main Authors: Muchtar, Eli, Gertz, Morie A., Magen, Hila
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
carfilzomib
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
combination regimen
Comorbidity
Drug Evaluation, Preclinical
Drug Resistance, Neoplasm
Humans
induction
multiple myeloma
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Oligopeptides - administration & dosage
Oligopeptides - adverse effects
Oligopeptides - pharmacokinetics
Oligopeptides - therapeutic use
proteasome inhibitors
Proteasome Inhibitors - administration & dosage
Proteasome Inhibitors - adverse effects
Proteasome Inhibitors - pharmacokinetics
Proteasome Inhibitors - therapeutic use
Recurrence
relapse
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carfilzomib, a second‐generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high‐risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.12749